Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | EML4 - NTRK3 |
Therapy | Entrectinib |
Indication/Tumor Type | thyroid gland papillary carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - NTRK3 | thyroid gland papillary carcinoma | predicted - sensitive | Entrectinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with papillary thyroid carcinoma harboring EML4-NTRK3 demonstrated a 69.7% decrease in disease burden after 34 cycles of treatment with Rozlytrek (entrectinib) (PMID: 32457407). | 32457407 |
PubMed Id | Reference Title | Details |
---|---|---|
(32457407) | Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC). | Full reference... |